Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,180.74 +52.95 (+1.03%) Dow
38,852.27 +176.59 (+0.46%) Nasdaq
16,349.25 +192.92 (+1.19%) Bitcoin USD
62,993.74 -1,183.58 (-1.84%) CMC Crypto 200
1,362.00 +49.38 (+3.76%)
Ascendis Pharma A/S (ASND)
After hours:
- Insider Monkey
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript May 4, 2024 Ascendis Pharma A/S isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to the Q1 2024 Ascendis Pharma Earnings Conference Call. At this time, all […]
- Simply Wall St.
Ascendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Ascendis Pharma ( NASDAQ:ASND ) First Quarter 2024 Results Key Financial Results Revenue: €95.9m (up 186% from 1Q...
- GlobeNewswire
Ascendis Pharma Reports First Quarter 2024 Financial Results
— Rollout of YORVIPATH® initiated in Germany and Austria, with an estimated 55 doctors writing prescriptions and ~100 patients receiving commercial product as of March 31 — TransCon™ PTH (palopegteriparatide) PDUFA date of May 14, 2024, for adults with hypoparathyroidism. If approved, U.S. launch planned in Q3 — TransCon CNP (navepegritide) pivotal ApproaCH Trial on track for topline results in Q4 2024 — SKYTROFA® Q1 revenue more than doubled year-over-year to €65 million; Q1 operating expenses
